Clinical guidelines for the prevention of colorectal cancer;Guía de práctica clínica sobre la prevención del cáncer colorrectal

Gastroenterologia y Hepatologia

Volumn 27, Issue 10, 2004, Pages 573-634

  Castells, A ^a   Marzo, M ^b   Bellas, B ^c   Amador, F J ^d   Lanas, A ^e   Mascort, J J ^f   Ferrandiz J ^g   Alonso, P ^b   Pinol V ^a   Fernandez M ^h   Bonfill, X ^b   Pique J M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Centro Cochrame Iberoamericano   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d Centro de Salud Los Rosales   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f ABS La Florida Sud del ICS   (Spain)

^g Instituto Madrileno de la Salud   (Spain)

^h Hospital Clinic   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CALCIUM; CAROTENOID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FOLIC ACID; GESTAGEN; SELENIUM; TRACE ELEMENT; VITAMIN B GROUP; VITAMIN D;

ADULT; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DESMOID TUMOR; DIETARY INTAKE; DUODENUM CARCINOMA; FAMILIAL COLON POLYPOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MACRONUTRIENT; MALE; PRACTICE GUIDELINE; REVIEW; SIGMOIDOSCOPY; TREATMENT INDICATION; COLORECTAL TUMOR; MASS SCREENING; METHODOLOGY; OCCULT BLOOD;

COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING; OCCULT BLOOD; PRACTICE GUIDELINES;

EID: 16644401147     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13069131     Document Type: Review

References (280)

1. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 2003; 169: 677-680.
2. a ed. Lyon: IARC Press, 2001.
3. Mortalidad por cáncer y otras causas en España, año 2000. Centre Nacional de Epidemiología, 2000. En: http://193.146.50.130/ cancer/cancerl.htm.
4. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
5. Piñol V, Andreu M, Castells A, Payá A, Bessa X, Jover R. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. A multicenter, prospective, nation-wide study. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Eur J Gastroenterol Hepatol [en prensa].
6. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A et al. Toward a comparison of survival in American and European cancer patients. Cancer 2000; 89: 893-900.
7. Ahlquist DA, Pasha TM. Clinical aspects of sporadic colorectal cancer. En: Rustgi AK, ed. Gastrointestinal cancers. Filadelfia: Saunders, 2003; 379-405.
8. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002; 31: 925-943.
9. Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 1997; 66: 1.564S-1.571S.
10. Norat T, Riboli E. Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 2003; 57: 1-17.
11. Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 2001; 10: 439-446.
12. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002; 98: 241-256.
13. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: an estimate of attributable and preventable fractions. IARC Sci Publ 2002; 156: 223-225.
14. Le Marchand L. Meat intake, metabolic genes and colorectal cancer. IARC Sci Publ 2002; 156: 481-485.
15. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78: 559S-569S.
16. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361: 1.496-1.501.
17. Michels KB, Edward G, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000; 92: 1.740-1.752.
18. Asano T, McLeod R. Dietary fibre for the prevention of colorectal adenomas and carcinomas (Cochrane Review). En: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd, 2003.
19. Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, Kulldorff M et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003; 361: 1.491-1.495.
20. Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 1998; 7: 163-168.
21. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002; 94: 437-446.
22. Hofstad B, Almendingen K, Vatn M, Andersen SN, Owen RW, Larsen S et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and anti-oxidants. Digestion 1998; 59: 148-156.
23. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340: 101-107.
24. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000; 356: 1.300-1.306.
25. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91: 2.102-2.106.
26. Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 2000; 11: 617-626.
27. Malila N, Virtamo J, Virtanen M, Pietinen P, Albanes D, Teppo L. Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers. Eur J Clin Nutr 2002; 56: 615-621.
28. Ritenbaugh C, Streit K, Helfand M. Routine supplementation to prevent cancer: a summary of the evidence from randomized controlled trials for the U.S. Preventive Task Force. En: http://www.ahcpr.gov/clinic/3rduspstf/vitamins/ vitasum.htm
29. Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr., Beck GJ, Bond JH, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994; 331: 141-147.
30. MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis P, Gratten H et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 1995; 87: 1.760-1.766.
31. Baron JA, Cole BF, Mott L, Haile R, Grau M, Church TR et al. Neoplastic and Antineoplastic Effects of beta-Carotene on Colorectal Adenoma Recurrence: Results of a Randomized Trial. J Natl Cancer Inst 2003; 95: 717-722.
32. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr., Slate EH, Fischbach LA et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11: 630-639.
33. IARC Working Group on the Evaluation of Cancer-Preventive Agents. Weight control and physical activity. Handbooks of cancer prevention, vol. 6. Lyon: IARC Press, 2002.
34. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001; 85: 1.700-1.705.
35. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 725-731.
36. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002; 252: 206-224.
37. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12; 88-93.
38. IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-steroidal anti-inflammatory drugs. Lyon: IARC Press, 1997.
39. Gatof D, Ahnen D. Primary prevention of colorectal cancer: diet and drugs. Gastroenterol Clin North Am 2002; 31: 587-623.
40. Vaisman N, Arber N. The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations. Best Pract Res Clin Gastroenterol 2002; 16: 201-217.
41. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1.220-1.224.
42. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720.
43. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
44. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998; 7: 653-659.
45. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-888.
46. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4: 191-210.
47. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-582.
48. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
49. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W et al. Noncardio-vascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
50. Grupo de trabajo de la guía de práctica clínica sobre rectorragia. Manejo del paciente con rectorragia. Guia de práctica clinica. Barcelona: Asociación Espanola de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2002. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 2.
51. Stellon AJ, Kenwright SE. Iron deficiency anaemia in general practice: presentations and investigations. Br J Clin Pract 1997; 51: 78-80.
52. Helfand M, Marton KI, Zimmer-Gembeck MJ, Sox HC Jr. History of visible rectal bleeding in a primary care population. Initial assessment and 10-year follow-up. JAMA 1997; 277: 44-48.
53. Scottish Intercollegiate Guidelines Network (SIGN). Management of colorectal cancer, 2003. En: http://www.sign.ac.uk/pdf/sign67.pdf
54. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560.
55. Marzo M. Diagnóstico rápido de cancer. Cuadernos de Gestión 2002; 25-36.
56. The NHS Plan. A plan for investment. A plan for reform. Department of Health; 2000. En: http://www.doh.gov.uk/nhsplan/nhsplan.pdf
57. Crosland A, Jones R. Rectal bleeding: prevalence and consultation behaviour. BMJ 1995; 311: 486-488.
58. Mor V, Masterson-Allen S, Goldberg R, Guadagnoli E, Wool MS. Pre-diagnostic symptom recognition and help seeking among cancer patients. J Community Health 1990; 15: 253-266.
59. Holliday HW, Hardcastle JD. Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet 1979; 1: 309-311.
60. Fernandez E, Porta M, Malais N, Belloc J, Gallen M. Symptom-to-diagnosis interval and survival in cancers of the digestive tract. Dig Dis Sci 2002; 47: 2.434-2.440.
61. Goodman D, Irvin TT. Delay in the diagnosis and prognosis of carcinoma of the right colon. Br J Surg 1993; 80: 1.327-1.329.
62. Potter MA, Wilson RG. Diagnostic delay in colorectal cancer. J R Coll Surg Edinb 1999; 44: 313-316.
63. Mansson J, Marklun B, Hultborn R. The diagnosis of cancer in the "roar" of potential cancer symptoms of patients in primary health care. Research by means of the computerised journal. Scand J Prim Health Care 2001; 19: 83-89.
64. Ransohoff DF, Lang CA. Screening for colorectal cancer. N Engl J Med 1991; 325: 37-41.
65. Rex DK, Johnson DA, Lieberman DA, Burt RW, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol 2000; 95: 868-877.
66. Rhodes JM. Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland. Gut 2000; 46: 746-748.
67. Burt RW. Colon cancer screening. Gastroenterology 2000; 119: 837-853.
68. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001; 51: 38-75.
69. Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2001; 165: 206-208.
70. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002; 52: 8-22.
71. Screening for colorectal cancer; recommendation and rationale. Ann Intern Med 2002; 137: 129-131.
72. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 132-141.
73. Screening for colorectal cancer in adults systematic evidence review. Agency for Healthcare Research and Quality, 2002. En: http://www.ahcpr.gov/ clinic/uspstf/uspscolo.htm
74. Walsh JM, Terdiman JP. Colorectal cancer screening: clinical applications. JAMA 2003; 289: 1.297-1.302.
75. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003; 289: 1.288-1.296.
76. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003; 53: 27-43.
77. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50: 840-844.
78. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1.365-1.371.
79. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1.472-1.477.
80. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1.467-1.471.
81. Towler B, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Systematic Review 2000; 2: CD001216.
82. Scholefield JH, Moss SM. Faecal occult blood screening for colorectal cancer. J Med Screen 2002; 9: 54-55.
83. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437.
84. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1.603-1.607.
85. Bini EJ, Rajapaksa RC, Weinshel EH. The findings and impact of nonrehydrated guaiac examination of the rectum (FINGER) study: a comparison of 2 methods of screening for colorectal cancer in asymptomatic average-risk patients. Arch Intern Med 1999; 159: 2.022-2.026.
86. Eisner MS, Lewis JH. Diagnostic yield of a positive fecal occult blood test found on digital rectal examination. Does the finger count? Arch Intern Med 1991; 151: 2.180-2.184.
87. Selby JV, Friedman GD, Quesenberry CP Jr., Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-657.
88. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 1.572-1.575.
89. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003; 95: 622-625.
90. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414-420.
91. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1.291-1.300.
92. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst 2002; 94: 1.763-1.772.
93. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71: 589-593.
94. Atkin WS, Hart A, Edwards R, McIntyre P, Aubrey R, Wardle J et al. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998; 42: 560-565.
95. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168.
96. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-174.
97. Lewis JD, Ng K, Hung KE, Bilker WB, Berlin JA, Brensinger C et al. Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med 2003; 163: 413-420.
98. Schoenfeld P, Lipscomb S, Crook J, Dominguez J, Butler J, Holmes L et al. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. Gastroenterology 1999; 117: 312-318.
99. Schroy PC, Heeren T, Bliss CM, Pincus J, Wilson S, Prout M. Implementation of on-site screening sigmoidoscopy positively influences utilization by primary care providers. Gastroenterology 1999; 117: 304-311.
100. Macafee DA, Scholefield JH. Antagonist: population based endoscopic screening for colorectal cancer. Gut 2003; 52: 323-326.
101. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85: 1.311-1.318.
102. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JM. Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 1998; 317: 182-185.
103. Scheitel SM, Ahlquist DA, Wollan PC, Hagen PT, Silverstein MD. Colorectal cancer screening: a community case-control study of proctosigmoidoscopy, barium enema radiography, and fecal occult blood test efficacy. Mayo Clin Proc 1999; 74: 1.207-1.213.
104. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342: 1.766-1.772.
105. Winawer SJ, Zauber AG, Church T, Mandelson M, Feld A, Bond J et al. National Colonoscopy Study (NCS) preliminary results: a randomized controlled trial of general population screening colonoscopy. Gastroenterology 2002; 122: A480 [abstract].
106. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155: 1.741-1.748.
107. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 1.954-1.961.
108. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328: 901-906.
109. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812-815.
110. Rex DK, Cummings OW, Helper DJ, Nowak TV, McGill JM, Chiao GZ et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons. Gastroenterology 1996; 111: 1.178-1.181.
111. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24-28.
112. Haseman JH, Lemmel GT, Rahmani EY, Rex DK. Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals. Gastrointest Endosc 1997; 45: 451-455.
113. Rembacken BJ, Fujii T, Cairns A, Dixon MF, Yoshida S, Chalmers DM et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 355: 1.211-1.214.
114. Brooker JC, Saunders BP, Shah SG, Thapar CJ, Thomas HJ, Atkin WS et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 56: 333-338.
115. Dunlop MG. Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years. Gut 2002; 51: V17-V20.
116. Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2.191-2.200.
117. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104.
118. Wardle J, Taylor T, Sutton S, Atkin W. Does publicity about cancer screening raise fear of cancer? Randomised trial of the psychological effect of information about cancer screening. BMJ 1999; 319: 1.037-1.038.
119. Stone EG, Morton SC, Hulscher ME, Maglione MA, Roth EA, Grimshaw JM et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med 2002; 136: 641-651.
120. Edwards A, Unigwe S, Elwyn G, Hood K. Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ 2003; 327: 703-709.
121. Propuesta de Recomendación del Consejo sobre cribado del cáncer. Comisión de las Comunidades Europeas, 2003. En: http://www.who.int/cancer/nccp/en/ecproposalforcouncilrecommendationes.pdf
122. Plan Integral del Cancer. Detección precoz. Dirección General Agencia de Calidad, 2003. (Borrador en fase de revisión).
123. Tarraga P, Garcia-Olmo D, Celada A, Garcia-Molinero M, Divison JA, Casado C. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone. Rev Esp Enferm Dig 1999; 91: 335-344.
124. Servicio de Prevención y Control del Cáncer. Programa piloto cribado del cáncer colorrectal en Hospitalet de Llobregat, periodo 2000-2002. Informe resultados primera ronda de cribado. Institut Català d'Oncologia, 2002.
125. Rustgi AK. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. N Engl J Med 1994; 331: 1.694-1.702.
126. Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypous, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51: V21-V27.
127. Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer 1994; 30A: 1.946-1.956.
128. Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavalieri J, Lynch J et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76: 2.427-2.433.
129. Giardiello FM, Brensinger JD, Luce MC, Petersen GM, Cayouette MC, Krush AJ et al. Phenotypic expression of disease in families that have mutations in the 5′ region of the adenomatous polyposis coli gene. Ann Intern Med 1997; 126: 514-519.
130. Brensinger JD, Laken SJ, Luce MC, Powell SM, Vance GH, Ahnen DJ et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 1998; 43: 548-552.
131. Gardner RJ, Kool D, Edkins E, Walpole IR, Macrae FA, Nasioulas S et al. The clinical correlates of a 3′ truncating mutation (codons 1982-1983) in the adenomatous polyposis coli gene. Gastroenterology 1997; 113: 326-331.
132. Soravia C, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62: 1.290-1.301.
133. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121: 198-213.
134. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003; 124: 1.574-1.594.
135. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332: 839-847.
136. Barel D, Cohen IJ, Mor C, Stern S, Shapiro R, Shomrat R et al. Mutations of the adenomatous polyposis coli and p53 genes in a child with Turcot's syndrome. Cancer Lett 1998; 132: 119-125.
137. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
138. Jarvinen HJ. Genetic testing for polyposis: practical and ethical aspects. Gut 2003; 52: 19ii-22.
139. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121: 195-197.
140. Laurent-Puig P, Beroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998; 26: 269-270.
141. Chikhaoui Y, Gelinas H, Joseph L, Lance JM. Cost-minimization analysis of genetic testing versus clinical screening of at-risk relatives for familial adenomatous polyposis. Int J Technol Assess Health Care 2002; 18: 67-80.
142. Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997; 336: 823-827.
143. Bulow S. Results of national registration of familial adenomatous polyposis. Gut 2003; 52: 742-746.
144. Berk T, Cohen Z, Bapat B, Gallinger S. Negative genetic test result in familial adenomatous polyposis: clinical screening implications. Dis Colon Rectum 1999; 42: 307-310 [discussion 310-312].
145. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group. Genet Med 2000; 2: 362-366.
146. Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102: 1.980-1.982.
147. Griffioen G, Bus PJ, Vasen HF, Verspaget HW, Lamers CB. Extracolonic manifestations of familial adenomatous polyposis: desmoid tumours, and upper gastrointestinal adenomas and carcinomas. Scand J Gastroenterol Suppl 1998; 225: 85-91.
148. Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen L, Griffioen G, Buskens E et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997; 40: 716-719.
149. Bjork J, Akerbrant H, Iselius L, Bergman A, Engwall Y, Wahlstrom J et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001; 121: 1.127-1.135.
150. Cahen DL, Fockens P, de Wit LT, Offerhaus GJ, Obertop H, Gouma DJ. Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Br J Surg 1997; 84: 948-951.
151. Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002; 50: 636-641.
152. Burke C. Risk stratification for periampullary carcinoma in patients with familial adenomatous polyposis: does theodore know what to do now? Gastroenterology 2001; 121: 1.246-1.248.
153. Pikaar A, Nortier JW, Griffioen G, Vasen HF. [Desmoid tumors in patients with familial adenomatous polyposis]. Ned Tijdschr Geneeskd 2002; 146: 1.355-1.359.
154. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932.
155. Giardiello FM, Offerhaus GJ, Krush AJ, Booker SV, Tersmette AC, Mulder JW et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 1991; 119: 766-768.
156. Giardiello FM, Petersen GM, Brensinger JD, Luce MC, Cayouette MC, Bacon J et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996; 39: 867-869.
157. Rhodes M, Bradburn DM. Overview of screening and management of familial adenomatous polyposis. Gut 1992; 33: 125-131.
158. Nugent KP, Northover JMA. Total colectomy and ileorectal anastomosis. En: Phillips RKS, Spigelman AD, Thomson JPS, eds. Familial adenomatous polyposis. Londres: Edward Arnold, 1994; 79-91.
159. Vasen HF, van der Luijt RB, Slors JF, Buskens E, de Ruiter P, Baeten CG et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996; 348: 433-435.
160. Bulow C, Vasen H, Jarvinen H, Bjork J, Bisgaard ML, Bulow S. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000; 119: 1.454-1.460.
161. Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001; 48: 515-521.
162. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1.313-1.316.
163. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639.
164. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1.618-1.619.
165. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1.946-1.952.
166. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1.960-1.968.
167. HuIs G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003; 362: 230-232.
168. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994; 107: 854-857.
169. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122: 641-645.
170. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995; 345: 855-856.
171. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860.
172. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD et al. Primary Chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1.054-1.059.
173. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560-570.
174. Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroentero-logy 2001; 121: 830-838.
175. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility
176. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 1994; 14: 1.631-1.634.
177. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-425.
178. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1.453-1.456.
179. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996; 2: 169-174.
180. Jass JR, Pokos V, Arnold JL, Cottier DS, Jeevaratnam P, Van de Water NS et al. Colorectal neoplasms detected colonoscopically in at-risk members of colorectal cancer families stratified by the demonstration of DNA microsatellite instability. J Mol Med 1996; 74: 547-551.
181. Jass JR, Cottier DS, Jeevaratnam P, Pokos V, Holdaway KM, Bowden ML et al. Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer. Lancet 1995; 346: 1.200-1.201.
182. Lewis CM, Neuhausen SL, Daley D, Black FJ, Swensen J, Burt RW et al. Genetic heterogeneity and unmapped genes for colorectal cancer. Cancer Res 1996; 56: 1.382-1.388.
183. Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1: 348-352.
184. Beck NE, Tomlinson IP, Homfray T, Hodgson SV, Harocopos CJ, Bodmer WF. Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg 1997; 84: 233-237.
185. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1.758-1.762.
186. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001; 135: 577-588.
187. Jarvinen HJ, Aamio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834.
188. Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995; 345: 1.183-1.184.
189. Lynch P. If aggressive surveillance in hereditary nonpolyposis colorectal cancer is now state of the art, are there any challenges left? Gastroenterology 2000; 118: 969-971.
190. Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82: 1.632-1.637.
191. Aamio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-218.
192. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277: 915-919.
193. Renkonen-Sinisalo L, Sipponen P, Aarnio M, Julkunen R, Aaltonen LA, Sama S et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002; 37: 574-577.
194. Dove-Edwin I, Boks D, Goff S, Renter GG, Carpenter R, Vasen HF et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94: 1.708-1.712.
195. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1.020-1.027.
196. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G et al. MSH2 mutation carriers are at higher risk of cancer than MLHl mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19: 4.074-4.080.
197. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer 1996; 69: 38-43.
198. Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J, Myrhoj T, Rozen P, Bertario L et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 1997; 225: 202-207.
199. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1.669-1.674.
200. St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES. Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993; 118: 785-790.
201. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334: 82-87.
202. Ahsan H, Neugut AI, Garbowski GC, Jacobson JS, Forde KA, Treat MR et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128: 900-905.
203. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2.992-3.003.
204. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst 1994; 86: 1.618-1.626.
205. Schoenfeld PS, Keith Fincher R, group ftMCCST. Colonoscopic surveillance of patients with a family history of colon cancer and a history of normal colonoscopy: is a five-year interval between colonoscopies appropriate? Clin Gastroenterol Hepatol 2003; 1: 310-314.
206. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin 1997; 47: 154-160.
207. Anwar S, White J, Hall C, Farrell WE, Deakin M, Elder JB. Sporadic colorectal polyps: management options and guidelines. Scand J Gastroenterol 1999; 34: 4-11.
208. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95: 3.053-3.063.
209. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98: 371-379.
210. Ward EM, Wolfsen HC. Review article: the non-inherited gastrointestinal polyposis syndromes. Aliment Pharmacol Ther 2002; 16: 333-342.
211. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1.447-1.453.
212. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
213. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002; 51: V6-V9.
214. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1.977-1.981.
215. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002; 89: 845-860.
216. Gschwantler M, Kriwanek S, Langner E, Goritzer B, Schrutka-Kolbl C, Brownstone E et al. High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. Eur J Gastroenterol Hepatol 2002; 14: 183-188.
217. Rex DK, Bond JH, Winawer S, Levin TR, Burt RW, Johnson DA et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2002; 97: 1.296-1.308.
218. Workshop PitP. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon. Gastrointest Endosc 2003; 58: s3-s43.
219. Dave S, Hui S, Kroenke K, Imperiale TF. Is the distal hyperplastic polyp a marker for proximal neoplasia? J Gen Intern Med 2003; 18: 128-137.
220. Jorgensen OD, Kronborg O, Fenger C. The Funen Adenoma Follow-Up Study. Characteristics of patients and initial adenomas in relation to severe dysplasia. Scand J Gastroenterol 1993; 28: 239-243.
221. van Stolk RU, Beck GJ, Baron JA, Haile R, Summers R. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology 1998; 115: 13-18.
222. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 2001; 120: 1.077-1.083.
223. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-662.
224. Jorgensen OD, Kronborg O, Fenger C. A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas. The Funen Adenoma Follow-up Study. Scand J Gastroenterol 1995; 30: 686-692.
225. Lund JN, Scholefield JH, Grainge MJ, Smith SJ, Mangham C, Armitage NC et al. Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut 2001; 49: 91-96.
226. Ransohoff DF, Lang CA, Kuo HS. Colonoscopic surveillance after polypectomy: considerations of cost effectiveness. Ann Intern Med 1991; 114: 177-182.
227. McKeown-Eyssen GE, Bright-See E, Bruce WR, Jazmaji V, Cohen LB, Pappas SC et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol 1994; 47: 525-536.
228. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000; 342: 1.149-1.155.
229. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000; 342: 1.156-1.162.
230. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95: 1.765-1.771.
231. Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea JA, Huttunen JK. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prev 1999; 8: 489-493.
232. Baden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
233. Ullman TA. Dysplasia and colorectal cancer in Crohn's disease. J Clin Gastroenterol 2003; 36: S75-S78.
234. Sharan R, Schoen RE. Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 2002; 31: 237-254.
235. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1.228-1.233.
236. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
237. Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1.356-1.362.
238. Delco F, Sonnenberg A. The unsolved problem of surveillance for colorectal cancer in ulcerative colitis. Can J Gastroenterol 1999; 13: 655-660.
239. Loftus EV Jr. Does monitoring prevent cancer in inflammatory bowel disease? J Clin Gastroenterol 2003; 36: S79-S83.
240. Baden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153.
241. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-714.
242. Choi PM, Nugent FW, Schoetz DJ Jr., Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424.
243. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51: V10-V12.
244. Inadomi JM. Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl 2003: 17-21.
245. Loftus EV Jr., Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998; 27: 685-690.
246. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888.
247. Matsumoto T, Nakamura S, Jo Y, Yao T, Iida M. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 2003; 98: 1.827-1.833.
248. Provenzale D, Wong JB, Onken JE, Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998; 93: 872-880.
249. Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000; 46: 500-506.
250. Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis. J Clin Gastroenterol 2001; 32: 99-105.
251. Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol 2003; 16: 347-358.
252. Goldblum JR. The histologic diagnosis of dysplasia, dysplasia-associated lesion or mass, and adenoma: a pathologist's perspective. J Clin Gastroenterol 2003; 36: S63-S69.
253. Friedman S, Odze RD, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 260-266.
254. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-74.
255. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944.
256. Gorfine SR, Bauer JJ, Harris MT, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum 2000; 43: 1.575-1.581.
257. Ullman TA, Loftus EV Jr., Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002; 97: 922-927.
258. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1.311-1.319.
259. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1.127-1.132.
260. Rubin P, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J et al. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1.295-1.300.
261. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol 1998; 22: 275-284.
262. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117: 1.288-1.294.
263. Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Am J Gastroenterol 1996; 91: 864-872.
264. Chawla A, Judge TA, Lichtenstein GR. Evaluation of polypoid lesions in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2002; 12: 525-534, ix.
265. Ziv Y, Fazio VW, Sirimarco MT, Lavery IC, Goldblum JR, Petras RE. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 1994; 37: 1.281-1.285.
266. Remzi FH, Fazio VW, Delaney CP, Preen M, Ormsby A, Bast J et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum often years. Dis Colon Rectum 2003; 46: 6-13.
267. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120.
268. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1.179-1.183.
269. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85.
270. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989; 97: 255-259.
271. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993; 119: 549-554.
272. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32.
273. Pardi DS, Loftus EV Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893.
274. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001; 4: 150-156.
275. Young GP, St John DJ, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO and OMED report. Am J Gastroenterol 2002; 97: 2.499-2.507.
276. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329: 1.982-1.987.
277. Li G, Tamura K, Yamamoto Y, Sashio H, Utsunomiya J, Yamamura T et al. Molecular and clinical study of familial adenomatous polyposis for genetic testing and management. J Exp Clin Cancer Res 1999; 18: 519-529.
278. Nagase H, Miyoshi Y, Horii A, Aoki T, Ogawa M, Utsunomiya J et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992; 52: 4.055-4.057.
279. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21: 1.698-1.707.
280. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5.248-5.257.